

# Platform Technology for Improving Ocular Drug Delivery


Ashim K. Mitra, Ph.D.

University of Missouri Curator's Professor of Pharmacy  
Chair, Division of Pharmaceutical Sciences,  
Vice-Provost for Interdisciplinary Research,  
Director of Translational Research at UMKC School of  
Medicine  
School of Pharmacy, University of Missouri-Kansas City




Missouri Technology Expo 2010  
Columbia, MO  
October, 7, 2010

# Eye




# Topical administration to retina: Cornea as a barrier




# RPE as a barrier


- Blood retinal barrier (oBRB)
  - Formed by the retinal pigment epithelium (RPE) to limit transport of molecules from choroidal circulation into the retina
  - Tight junctions are expressed between the RPE cells
  - Evidence also suggests the expression of P-gp on the basolateral side of RPE, limiting transport of substances from blood into the eye
- Inner blood retinal barrier (iBRB)



# Circumvention of efflux by prodrug derivatization



# Transporter targeted drug delivery to retina: systemic administration



D: Drug; ILM: Internal limiting membrane; P: Prodrug; RPE: Retinal pigmented epithelium

# Technology

- Present invention provides di- and tri-peptide mono- and di-ester prodrugs which have sufficient physicochemical properties to be formulated into pharmacologically active compositions such as aqueous solutions, e.g., eye drops.
- These compounds can be effectively transported into the ocular tissues by evading the efflux by efflux proteins (e.g., P-gp, MRPs) and utilizing nutrient transporters (e.g., peptide, aminoacid and vitamin transporters).
- These compounds can effectively reach the anterior segment and/or posterior segment following topical or systemic administrations.

# Technology



US007553812B2

(12) **United States Patent**  
**Mitra**

(10) **Patent No.:** **US 7,553,812 B2**  
(45) **Date of Patent:** **Jun. 30, 2009**

(54) **ACYCLOVIR-PEPTIDE ANALOGS**

(75) Inventor: **Ashim K. Mitra**, Overland Park, KS (US)

(73) Assignee: **The Curators of the University of Missouri**, Columbia, MO (US)

(\* ) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 706 days.

(21) Appl. No.: **10/854,533**

(22) Filed: **May 26, 2004**

(65) **Prior Publication Data**  
US 2005/0043246 A1 Feb. 24, 2005

#### Related U.S. Application Data

(63) Continuation of application No. PCT/US02/38846, filed on Dec. 4, 2002.

(60) Provisional application No. 60/336,666, filed on Dec. 4, 2001.

(51) **Int. Cl.**  
**A61K 38/16** (2006.01)  
**A61K 38/00** (2006.01)

(52) **U.S. Cl.** ..... **514/8**; 424/1.69; 514/2

(58) **Field of Classification Search** ..... 514/8  
See application file for complete search history.

(56) **References Cited**

#### U.S. PATENT DOCUMENTS

5,405,850 A 4/1995 Blumenkopf ..... 514/262  
7,214,664 B2 5/2007 Mitra et al.  
2006/0135438 A1 6/2006 Mitra et al.

#### OTHER PUBLICATIONS

Gao et al. Regioselective synthesis of various prodrugs of ganciclovir. Tetrahedron Letter (2000), 41(8), 1131-1136 (cited in R/T PCT/US02/38846 Search Report).\*

Lee, V.H. Membrane transporters. Eur. J. Pharm Sci. Oct. 2000, 11 Suppl 2: S41-50 (Applicant Mitra co-authored).\*

Han, H., "5'-Amino Acid Esters of Antiviral Nucleosides, Acyclovir, and AZT Are Absorbed by the Intestinal PEPT1 Peptide Transporter". *Pharmaceutical Research* 15 1998; 1154-1159.\*

Colla, Leon, et al., "Synthesis and antiviral activity of water-soluble esters of acyclovir [9-[2-hydroxyethoxy)methyl]guanine]". *Journal of Medicinal Chemistry*, 26(4), (Apr. 1983), pp. 602-604.

Lee, Vincent H., "Membrane transporters". *European Journal of Pharmaceutical Sciences*, 11 Suppl 2, (Oct. 2000), pp. S41-50.

Dey, Surajit , et al., "Molecular Evidence and Functional Expression of P-Glycoprotein (MDR1) in Human and Rabbit Cornea and Corneal Epithelial Cell Lines". *Investigative Ophthalmology & Visual Science*, vol. 44, No. 7, (Jul. 2003),2909-2918.

Fricker, Gert , "Modulation of Drug Transporters at the Blood-Brain Barrier". *Pharmacology*, vol. 70, (170-176),2004.

Gaucher, Berandere , "Prodrugs of HIV protease inhibitors-saquinavir, indinavir and nelfinavir-derived from diglycerides or amino acids: synthesis, stability and anti-HIV activity". *The Royal Society of Chemistry, Org. Biomol. Chem.*, vol. 2, (2004),345-357.

Irvine, Jennifer D., "MDCK (Madin-Darby Canine Kidney) Cells: A Tool for Membrane Permeability Screening". *Journal of Pharmaceutical Sciences*, vol. 88, No. 1., (Jan. 1999),28-33.

Jain, Ritesh , et al., "Evasion of P-gp mediated cellular efflux and permeability enhancement of HIV-protease inhibitor saquinavir by prodrug modification". *International Journal of Pharmaceutics* 303, (Aug. 30, 2005),8-19.

Rouquayrol, Marielle , "Transepithelial Transport of Prodrugs of the HIV Protease Inhibitors Saquinavir, Indinavir and Nelfinavir across Caco-2 Cell Monolayers". *Pharmaceutical Research*, vol. 19, No. 11, (Nov. 2002),1704-1712.

Vierling, Pierre , "Prodrugs of HIV Protease Inhibitors". *Current Pharmaceutical Design*, vol. 9, (2003),1775-1770.

Han, H., "5'-Amino Acid Esters of Antiviral Nucleosides, Acyclovir, and AZT Are Absorbed by the Intestinal PEPT1 Peptide Transporter". *Pharmaceutical Research*, 15, (1998),1154-1159.

Jain, R. , et al., "Circumventing P-glycoprotein-mediated cellular efflux of quinidine by prodrug derivatization". *Molecular Pharmaceutics*, 1(4), (Jul.-Aug. 2004),290-299.

"International Preliminary Examination Report Dec. 20, 2004".

"International Search Report Jul. 21, 2003".

"Non-Final Office Action Jul. 25, 2006".

"Notice of Allowance Mar. 26, 2007".

"Response to Non-Final Office Action Nov. 21, 2006".

\* cited by examiner

*Primary Examiner*—Cecilia Tsang

*Assistant Examiner*—Maury Audet

(74) *Attorney, Agent, or Firm*—Schwegman, Lundberg & Woessner, P.A.

(57) **ABSTRACT**

Dipeptide and tripeptide ester derivatives of acyclovir and its analogs are disclosed which are useful to treat herpes virus infections. Also disclosed is a method for preparing a therapeutic agent for targeted delivery to ocular tissue comprising linking the therapeutic agent to one or more groups of the formula -X-Y-Z<sub>(n)</sub>-R; wherein each X, Y and Z is independently Met, Val, Thr, Tyr, Trp, Ser, Ala or Gly; each R is independently H or an amino-protecting group; and each n is independently 0 or 1.

**26 Claims, 18 Drawing Sheets**



# Technology



US007214664B2

(12) **United States Patent**  
**Mitra et al.**

(10) **Patent No.:** **US 7,214,664 B2**  
(45) **Date of Patent:** **May 8, 2007**

(54) **PEPTIDYL PRODRUGS THAT RESIST P-GLYCOPROTEIN MEDIATED DRUG EFFLUX**

(75) Inventors: **Ashim K. Mitra**, Overland Park, KS (US); **Soumyajit Majumdar**, Oxford, MS (US); **Ritesh Jain**, Kansas City, MO (US); **Yasser Nashed**, Thousand Oaks, CA (US)

(73) Assignee: **The Curators of the University of Missouri**, Columbia, MO (US)

(\* ) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **11/285,754**

(22) Filed: **Nov. 22, 2005**

(65) **Prior Publication Data**  
US 2006/0135438 A1 Jun. 22, 2006

**Related U.S. Application Data**

(60) Provisional application No. 60/633,366, filed on Dec. 3, 2004.

(51) **Int. Cl.**  
**A61K 31/00** (2006.01)

(52) **U.S. Cl.** ..... **514/19; 540/557**

(58) **Field of Classification Search** ..... None  
See application file for complete search history.

(56) **References Cited**

**U.S. PATENT DOCUMENTS**

5,405,850 A 4/1995 Blumenkopf  
2005/0043246 A1 2/2005 Mitra

**FOREIGN PATENT DOCUMENTS**

WO WO-03/048190 6/2003

**OTHER PUBLICATIONS**

Jain, R. et al., "Circumventing P-Glycoprotein-Mediated Cellular Efflux of Quinidine by Prodrug Derivatization", 2004, *Molecular Pharmaceutics*, vol. 1:290-299.\*  
Vierling, P. et al., "Prodrugs of HIV Protease Inhibitors", Aug. 2003, *Current Pharmaceutical Design*, vol. 9:1755-1770.\*  
Colla, Leon, et al., "Synthesis and antiviral activity of water-soluble esters of acyclovir [9-(2-hydroxyethoxy)methyl]guanine]", *Journal of Medicinal Chemistry*, 26(4), (Apr. 1983),602-4.

Dey, Surajit, et al., "Molecular Evidence and Functional Expression of P-Glycoprotein (MDR1) in Human and Rabbit Cornea and Corneal Epithelial Cell Lines", *Investigative Ophthalmology & Visual Science*, vol. 44, No. 7, (Jul. 2003), 2909-2918.

Fricker, Gert, "Modulation of Drug Transporters at the Blood-Brain Barrier", *Pharmacology*, vol. 70, (170-176),2004.

Gaucher, Berandere, "Prodrugs of HIV protease inhibitors-saquinavir, indinavir and nelfinavir-derived from diglycerides or amino acids: synthesis, stability and anti-HIV activity", *The Royal Society of Chemistry, Org. Biomol. Chem.*, vol. 2, (2004),345-357.  
Irvine, Jennifer D., "MDCK (Madin-Darby Canine Kidney) Cells: A Tool for Membrane Permeability Screening", *Journal of Pharmaceutical Sciences*, vol. 88, No. 1., (Jan. 1999),28-33.

Jain, Ritesh, et al., "Evasion of P-gp mediated cellular efflux and permeability enhancement of HIV-protease inhibitor saquinavir by prodrug modification", *International Journal of Pharmaceutics* 303, (Aug. 30, 2005),8-19.

Lee, Vincent H., "Membrane transporters", *European Journal of Pharmaceutical Sciences*, 11 Suppl 2, (Oct. 2000),S41-50.

Rouquayrol, Marielle, "Transepithelial Transport of Prodrugs of the HIV Protease Inhibitors Saquinavir, Indinavir and Nelfinavir across Caco-2 Cell Monolayers", *Pharmaceutical Research*, vol. 19, No. 11 (Nov. 2002),1704-1712.

Vierling, Pierre, "Prodrugs of HIV Protease Inhibitors", *Current Pharmaceutical Design*, vol. 9, (2003),1755-1770.

Gao, Hongwu, et al., "Regioselective synthesis of various prodrugs of ganciclovir", *Tetrahedron Letters*, 41(8), (2000),1131-1136.

Han, H., "S-Amino Acid Esters of Antiviral Nucleosides, Acyclovir, and AZT Are Absorbed by the Intestinal PEPT1 Peptide Transporter", *Pharmaceutical Research*, 15, (1998), 1154-1159.

\* cited by examiner

*Primary Examiner*—B. Dell Chism

*Assistant Examiner*—Hemant Khanna


(74) *Attorney, Agent, or Firm*—Schwegman, Lundberg, Woessner & Kluth P.A.

(57) **ABSTRACT**

Dipeptide, and tripeptide and tetrapeptide ester derivatives of bioactive agents are provided wherein the parent agents are substrates effluxed by the P-gp transporter. The derivatives are useful in treating the same condition as the bioactive agent. Also disclosed is a method for preparing a bioactive agent for targeted delivery by nutrient or peptide transporters comprising linking the agent to one or more groups of the formula —X—Y<sub>(n)</sub>—Z<sub>(m)</sub>—Z'<sub>(n')</sub>—R; wherein each X, Y, Z, and Z' is independently Met, Val, Thr, Tyr, Trp, Ser, Ala or Gly; R is independently H or an amino-protecting group; n=1, and each, n', or n" is independently 0 or 1.

**9 Claims, 9 Drawing Sheets**


# Structures




Acyclovir

R-promoiety


Substitutions of R:




Valine




Valine-Valine




Glycine-Glycine



Glycine-Valine




Tyrosine-Valine



Valine-Tyrosine

# Time course of corneal permeation of cumulative amount of ACV, L-Val-ACV, VVACV across rabbit cornea.



# Transport Characteristics of Prodrugs

---


Drug	$P_{app} \times 10^6 \text{ cm/sec}$ ( $\pm$ S.D)
ACV	4.24 ( $\pm$ 1.41) <sup>a</sup>
VACV	12.1 ( $\pm$ 0.44)*
VVACV	9.91 ( $\pm$ 2.40)*
GVACV	12.4 ( $\pm$ 1.42)*
YVACV	7.19 ( $\pm$ 1.38)*
VYACV	8.34 ( $\pm$ 1.12)*

---


<sup>a</sup> control

\*  $p < 0.05$


# Anterior chamber levels of ACV following systemic administration of ACV, VACV, and VVACV




# Regeneration of the Prodrug



Regeneration of ACV from Val-Val-ACV upon subsequent hydrolysis to VACV in isolated rabbit cornea



**Possible mechanisms of enzymatic hydrolysis of di-peptide prodrug, Val-Val-ACV to Acyclovir in cornea. Val-Val-ACV prodrug is sequentially hydrolyzed via Val-ACV to yield the parent drug ACV. The hydrolysis is mainly enzymatic and not chemical as Val-Val-ACV is relatively more stable in IPBS (pH 7.4,  $t_{1/2} \approx 108$  hrs.)**



## Stereoisomeric prodrugs of ACV


- Systemic drug delivery (intravenous or oral) is potentially an effective route to treat various systemic as well as ocular disorders. However, drugs administered by this route must cross the intestine to reach the systemic circulation and subsequently the blood ocular barriers (BOB) to reach the inner ocular tissues.
- Limited therapeutic efficacy of ACV against herpes infections following oral administration is due to its poor permeability across oral mucosa. Several studies proved that oral bioavailability of ACV can be improved by prodrug derivatization.



## Stereoisomeric prodrugs of ACV

- Amino acid and dipeptide prodrugs of ACV that have been evaluated before were found to be metabolized rapidly and completely to the parent drug during first pass following oral administration.
- However, regenerated ACV has to cross Blood Aqueous Barrier (BAB) to permeate into the anterior chamber ocular tissues. So there is a necessity to design prodrugs such that their hydrolytic rate can be modulated to generate higher amounts of intact prodrug in the systemic circulation resulting from improved oral bioavailability.
- Hence we synthesized stereoisomeric dipeptide prodrugs of ACV (L-val-L-val- ; L-val-D-val- ; D-val-L-val-; D-val-D-val- )

## Stereoisomeric prodrugs of ACV




Apparent permeability of ACV Stereoisomeric prodrugs across Caco-2. Each value is represented as mean±S.D. ( $n = 4$ ).

Drug	$K \times 10^3$ ( $h^{-1}$ )	$t_{1/2}$ (h)
LL-ACV	-	<0.08
LD-ACV	$688.23 \pm 48.68$	$1.01 \pm 0.07$
DL-ACV	$110.06 \pm 4.52$	$6.27 \pm 0.25$
DD-ACV	ND	ND


Stability of ACV prodrugs in rat intestinal homogenate – first-order degradation rate constants and half lives of all prodrugs.

“ND” Represents no degradation during the time of study. Symbol “-” represents the whole prodrug degraded in less than first sampling time point (5 min). Each value is represented as mean±S.D. ( $n = 3$ ).

## Corneal absorption of ACV prodrugs following oral administration



Corneal uptake of ACV following oral administration of LDACV and LACV in rats. (Each value represents mean  $\pm$  SD).



Corneal concentrations of LDACV and ACV following oral administration of LDACV at a molar dose equivalent to 30 mg/kg of acyclovir in rats ( $\blacksquare$ -ACV,  $\square$ -LDACV). Values are represented as mean  $\pm$  SD, n = 3-4 [R-right eye, L-left eye].

# Conclusions

- The dipeptide prodrugs of ACV were highly permeable across cornea as compared to ACV.
- Studies conducted in our laboratory have shown that these dipeptide ester prodrugs are less toxic (no cytotoxicity detected within the concentration range studied) as compared to TFT and ACV.
- The dipeptide prodrug Val-Val-ACV has also shown excellent in vivo activity against rabbit stromal keratitis, which is not adequately treated by current antiviral therapeutic regimens. Val-Val-ACV has been shown to be as efficacious as TFT at a much lower molar concentration in the rabbit stromal keratitis model.
- The stereoisomeric prodrug L-val-D-val-ACV exhibited good enzymatic stability and improved ocular absorption following oral administration.
- This technology can be utilized to improve ocular bioavailability of various drugs following both topical and oral administration in order to treat several ocular infections and disease conditions.

Thank you

&

Questions